Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Modakafusp alfa - Takeda/Teva Pharmaceutical Industries

Next Previous
Search
Drug Profile

Modakafusp alfa - Takeda/Teva Pharmaceutical Industries

Alternative Names: TAK-573; TEV-48573

Latest Information Update: 07 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Developer Takeda
  • Class Antibodies; Antineoplastics; Immunoglobulin fragments; Immunotherapies; Interferons; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant melanoma; Multiple myeloma; Solid tumours

Most Recent Events

  • 07 Dec 2024 Final efficacy and adverse events data from a phase I/II trial in Multiple myeloma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
  • 07 Nov 2024 Takeda completes a phase I/II trial in Multiple myeloma (Monotherapy, Second-line therapy or greater) in USA, China, Germany, Greece, France, Israel, Italy, Japan, South Korea, Italy, Norway, Puerto Rico, Spain, Turkey, United Kingdom and Canada (IV) (NCT03215030)
  • 04 Jun 2024 Takeda completes a phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Austria, Belgium, Canada, Israel, Italy, Spain and the United Kingdom (IV) (NCT05556616) (EudraCT2022-001418-20)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top